Alpha Synuclein - Pipeline Review, H2 2019
Alpha Synuclein - Pipeline Review, H2 2019
SUMMARY
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 9, 19 and 10 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Lewy Body Dementia, Familial Amyloid Neuropathies, Amyloidosis, Constipation, Dementia, Dementia Associated With Alzheimer's Disease, Down Syndrome, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Schizophrenia, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
The latest report Alpha Synuclein - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 9, 19 and 10 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Lewy Body Dementia, Familial Amyloid Neuropathies, Amyloidosis, Constipation, Dementia, Dementia Associated With Alzheimer's Disease, Down Syndrome, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Schizophrenia, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Type 2 Diabetes.
The latest report Alpha Synuclein - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
AbbVie Inc
AC Immune SA
AFFiRiS AG
Annovis Bio Inc
Arvinas Inc
AstraZeneca Plc
Biogen Inc
Denali Therapeutics Inc
Enterin Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
Neuropore Therapies Inc
nLife Therapeutics SL
Prevail Therapeutics Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
Seelos Therapeutics Inc
UCB SA
United Neuroscience Ltd
Voyager Therapeutics Inc
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
ABBV-0805 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANVS-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANVS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASOA-19 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1947D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1948D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1949D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinpanemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapies to Inhibit SNCA for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Neurodegerative Diseases Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCB-0599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics Development
AbbVie Inc
AC Immune SA
AFFiRiS AG
Annovis Bio Inc
Arvinas Inc
AstraZeneca Plc
Biogen Inc
Denali Therapeutics Inc
Enterin Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
Neuropore Therapies Inc
nLife Therapeutics SL
Prevail Therapeutics Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
Seelos Therapeutics Inc
UCB SA
United Neuroscience Ltd
Voyager Therapeutics Inc
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles
ABBV-0805 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABL-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANVS-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANVS-405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASOA-19 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1947D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1948D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1949D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950D - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-1950R - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibodies to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cinpanemab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapies to Inhibit SNCA for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LuAF-82422 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-1341 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
prasinezumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLS-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Neurodegerative Diseases Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trehalose - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UB-312 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCB-0599 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by AC Immune SA, H2 2019
Pipeline by AFFiRiS AG, H2 2019
Pipeline by Annovis Bio Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Denali Therapeutics Inc, H2 2019
Pipeline by Enterin Inc, H2 2019
Pipeline by Fulcrum Therapeutics Inc, H2 2019
Pipeline by Genmab A/S, H2 2019
Pipeline by ICB International Inc, H2 2019
Pipeline by Neuropore Therapies Inc, H2 2019
Pipeline by nLife Therapeutics SL, H2 2019
Pipeline by Prevail Therapeutics Inc, H2 2019
Pipeline by Priavoid GmbH, H2 2019
Pipeline by ProMIS Neurosciences Inc, H2 2019
Pipeline by Prothena Corp Plc, H2 2019
Pipeline by Seelos Therapeutics Inc, H2 2019
Pipeline by UCB SA, H2 2019
Pipeline by United Neuroscience Ltd, H2 2019
Pipeline by Voyager Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by AC Immune SA, H2 2019
Pipeline by AFFiRiS AG, H2 2019
Pipeline by Annovis Bio Inc, H2 2019
Pipeline by Arvinas Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Denali Therapeutics Inc, H2 2019
Pipeline by Enterin Inc, H2 2019
Pipeline by Fulcrum Therapeutics Inc, H2 2019
Pipeline by Genmab A/S, H2 2019
Pipeline by ICB International Inc, H2 2019
Pipeline by Neuropore Therapies Inc, H2 2019
Pipeline by nLife Therapeutics SL, H2 2019
Pipeline by Prevail Therapeutics Inc, H2 2019
Pipeline by Priavoid GmbH, H2 2019
Pipeline by ProMIS Neurosciences Inc, H2 2019
Pipeline by Prothena Corp Plc, H2 2019
Pipeline by Seelos Therapeutics Inc, H2 2019
Pipeline by UCB SA, H2 2019
Pipeline by United Neuroscience Ltd, H2 2019
Pipeline by Voyager Therapeutics Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
AC Immune SA
AFFiRiS AG
Annovis Bio Inc
Arvinas Inc
AstraZeneca Plc
Biogen Inc
Denali Therapeutics Inc
Enterin Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
Neuropore Therapies Inc
nLife Therapeutics SL
Prevail Therapeutics Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
Seelos Therapeutics Inc
UCB SA
United Neuroscience Ltd
Voyager Therapeutics Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
AC Immune SA
AFFiRiS AG
Annovis Bio Inc
Arvinas Inc
AstraZeneca Plc
Biogen Inc
Denali Therapeutics Inc
Enterin Inc
Fulcrum Therapeutics Inc
Genmab A/S
ICB International Inc
Neuropore Therapies Inc
nLife Therapeutics SL
Prevail Therapeutics Inc
Priavoid GmbH
ProMIS Neurosciences Inc
Prothena Corp Plc
Seelos Therapeutics Inc
UCB SA
United Neuroscience Ltd
Voyager Therapeutics Inc
